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Abstract
RAS mutant (MT) metastatic colorectal cancer (mCRC) is resistant to MEK1/2 inhibition and remains a difficult-to-treat
group. Therefore, there is an unmet need for novel treatment options for RASMT mCRC. RALA and RALB GTPases
function downstream of RAS and have been found to be key regulators of several cell functions implicated in KRAS-
driven tumorigenesis. However, their role as regulators of the apoptotic machinery remains to be elucidated. Here, we
found that inhibition of RALB expression, but not RALA, resulted in Caspase-8-dependent cell death in KRASMT CRC
cells, which was not further increased following MEK1/2 inhibition. Proteomic analysis and mechanistic studies
revealed that RALB depletion induced a marked upregulation of the pro-apoptotic cell surface TRAIL Death Receptor 5
(DR5) (also known as TRAIL-R2), primarily through modulating DR5 protein lysosomal degradation. Moreover, DR5
knockdown or knockout attenuated siRALB-induced apoptosis, confirming the role of the extrinsic apoptotic pathway
as a regulator of siRALB-induced cell death. Importantly, TRAIL treatment resulted in the association of RALB with the
death-inducing signalling complex (DISC) and targeting RALB using pharmacologic inhibition or RNAi approaches
triggered a potent increase in TRAIL-induced cell death in KRASMT CRC cells. Significantly, high RALBmRNA levels were
found in the poor prognostic Colorectal Cancer Intrinsic Subtypes (CRIS)-B CRC subgroup. Collectively, this study
provides to our knowledge the first evidence for a role for RALB in apoptotic priming and suggests that RALB
inhibition may be a promising strategy to improve response to TRAIL treatment in poor prognostic RASMT CRIS-B CRC.
Introduction
Mutations in RAS (KRAS and NRAS) in exon 2 (codon
12, 13), 3 (codon 59, 61) and 4 (codon 117, 146) occur in
55–60% of colorectal cancer (CRC) patients1 and have
been associated with poor survival2. Activating mutations
in RAS lead to aberrant activation of RAS downstream
effector signalling either by increasing its intrinsic GDP/
GTP exchange rate or by reducing the rate of its intrinsic
and GTP-ase activating protein (GAP)-induced hydro-
lysis3. RAS has proven difficult to target and inhibition of
its downstream effectors MEK1/2 and AKT/PI3K has
been shown to be ineffective in RAS mutant (MT) CRC4,5.
Like RAS, the RAS-like (RAL) small GTPases RALA and
RALB are activated by RAL-selective guanine nucleotide
exchange factors (RAL-GEFs), such as the RAL guanine
nucleotide dissociation stimulator (RALGDS), and are
inactivated by GTPase activating proteins (RALGAPs).
RALGDS couples RAS to the RAL proteins, stimulating
the GDP/GTP exchange of RAL. In their active
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GTP-bound state, RALA and RALB can interact with a
range of functionally different effectors, including
RALBP1, EXO84 and SEC5, two distinct subunits of the
hetero-octomeric exocyst complex, as well as with ZO-1-
associated nucleic acid-binding protein (ZONAB)6. Pre-
vious studies have established the requirement for RAL-
GEFs for the transformation of human epithelial cells7,8.
Using a KRAS-driven murine lung carcinoma model,
other investigators have shown that RALA or RALB
activity is required for tumour growth9. RALA and RALB
have also been shown to have opposing and/or distinct
roles in migration and anchorage-independent growth in
bladder, prostate and pancreatic cancer, respectively10–12.
In this study, we report a novel role for RALB in reg-
ulating Death Receptor 5 (DR5) protein levels and cell
death in KRASMT CRC. Cellular and mechanistic studies
indicate that RALB associates with DR5 and the death-
inducing signalling complex (DISC) in a ligand-dependent
manner, and that inhibition of RALB combined with DR5
agonists can be a novel treatment strategy for poor




AZD6244, recombinant human (rh)TRAIL and z-VAD-
FMK were purchased from AstraZeneca (Macclesfield,
UK), Calbiochem (Hertfordshire, UK) and Sigma-Aldrich
(Gillingham, Dorset, UK), respectively. Isoleucine-zipper
TRAIL (iz-TRAIL) was expressed and purified in-house14.
iz-TRAIL is a modified form of rhTRAIL that comprises
an isoleucine zipper motif fused to its N-terminus, which
enhances its ability to trimerise — a process required for
its apoptotic activity, consequently increasing its potency.
siRNA sequences targeting RALA (_8 SI03101133), RALB
(_1 S100045199; _4 SI00045178; _6 SI03054793; _7
SI03117492), RALGDS (_5 SI03231424), Caspase-8 (_11
SI02661946) and Caspase-9 (_5 SI00299600) were pur-
chased from Qiagen (Crawley, UK). siRNA sequences
targeting DR4 and DR5 were purchased from Dharmacon.
TRAIL neutralising antibody, Chloroquine and Bafilo-
mycin A1 were purchased from R&D systems (Abingdon,
UK), Invivogen (San Diego, CA) and Merck Millipore
(Darmstadt, Germany), respectively.
Cell culture
Authentication and culture of the HCT116, SW620,
GP5d, LoVo, LIM1215 and COLO320 CRC cells have
previously been described15,16. KM12 cells were obtained
from the National Cancer Institute-Frederick, Cancer
DCT Tumour repository (authentication: SNP arrays,
oligonucleotide-base HLA typing, karyotyping and STR)
and maintained in Roswell Park Memorial Institute 1640
(RPMI). DiFi, SW403, NCI-498 and HDC8 CRC cells
were obtained from Dr. Montagut (Barcelona, Spain) and
Prof. Bardelli, respectively17,18. HCT116 Caspase-8 wild-
type (WT) and null paired cells, DR5 parental and
knockout cells, and p53 parental and matched isogenic
p53 null CRC cells were a gift from Prof. G. Lahav
(Harvard Medical School, Boston)19, Prof. M. Rehm (Uni-
versity of Stuttgart) and Prof. B. Vogelstein (Johns Hopkins
University, Baltimore), respectively, and were grown in
McCoy’s 5 A Modified Medium. All cells were passaged for
a maximum of two months. Cell lines were tested for
mycoplasma contamination every month using the
MycoAlert™ Mycoplasma Detection Kit (Lonza).
Western blotting
Western blotting and antibodies have previously been
described15. Antibodies were used in conjunction with a
HRP-conjugated anti-rabbit or anti-mouse secondary
antibody. β-actin was used as a sample loading control.
Details of the antibodies used have been included in Table
S1. Western blot images were developed using the G:BOX
Chemi XX6 gel doc system (Syngene). Densitometry on
western blot images was performed using ImageJ
software.
DR5-DISC IP assay
The DR5-DISC IP assay was performed as previously
published20. The fully human agonistic DR5 antibody
AMG 655 (Conatumumab; Amgen, Thousand Oaks, CA,
USA) was conjugated to Dynabeads using the Dyna-
beads® antibody coupling kit (Life Technologies, Paisley,
UK) as per the manufacturer’s instructions. To the cells,
30 μL of AMG 655-conjugated Dynabeads® was added
for the indicated time. The cells were lysed in lysis buffer
(0.2% NP-40, 20 mM Tris, 150mM NaCl, 10% glycerol;
pH 7.4) supplemented with protease inhibitors. The AMG
655-conjugated Dynabeads® were captured magnetically,
washed in lysis buffer, resuspended in Laemmli buffer and
analysed by western blotting. Unbound fractions (inputs)
were also collected and analysed by western blotting.
FLAG-co-immunoprecipitation
Protein lysates were prepared using SDS-free RIPA
(50 mM Tris, 150 mM NaCl, 1% Triton X-100 and 5mM
EDTA, pH 7.4). Lysates were incubated with anti-FLAG®
M2 Magnetic beads (Sigma) overnight and isolated using
a magnetic rack. After several washes, beads were resus-
pended in Laemmli buffer and heated at 95 °C for
5 minutes prior to immunoblot analysis.
RALB activity assay
GTP-bound RALB was isolated from whole cell lysates
using a RALB activation Assay Kit (Merck Millipore). The
assay was performed according to the manufacturer’s
instructions.
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Expression constructs and transfection
FLAG-tagged WT and constitutively active (G23V)
RALB constructs were provided by Prof. Dan Theodor-
escu (Denver University, Colorado)21. Site-directed
mutagenesis to generate the other RALB mutants
(S28N, C203S) was performed using the KOD Xtreme™
Hot Start DNA Polymerase kit (Merck Millipore). DNA
transfection was carried out using XtremeGene-HP
reagent (Roche).
Proteome Profiler Human Apoptosis Array Kit
Array was analysed according to the manufacturer’s
instructions (R&D systems, Abingdon). Array densito-
metry was performed on the duplicate ‘spots’ using Ima-
geJ software. Background intensity was subtracted from
raw pixel density values. Normalised pixel density values
were represented as a ‘fold-change’ relative to the control
values, with error bars representing standard deviation
from the mean.
Flow cytometry
Apoptosis was evaluated using propidium iodide (PI)
staining to determine the percentage of cells with DNA
content <2N (sub-G1)15. The BD FACS Calibur Flow Cyt-
ometer (BD Biosciences) and Cell Quest Pro Software was
used to perform PI staining flow cytometry. DR5 cell -surface
expression flow cytometry was performed using a phycoer-
ythrin (PE)-conjugated DR5-specific antibody (12-9908-42,
ThermoFisher Scientific) and a matched isotype control
antibody (12-4714-41, ThermoFisher Scientific). The BD
FACS Calibur Flow Cytometer and Cell Quest Pro Software
were used to analyse geometric means for cell surface
expression. Ten thousand events were counted per experi-
ment for all the flow cytometry experiments.
High content screening
Annexin V (AV)/PI staining was evaluated using high
content screening and performed in a 96-well plate (glass-
bottomed plates, Cell Vis) format. Cells were seeded and
treated as required (each treatment was performed in
triplicate). Post-treatment, 1x AV Binding Buffer (10x
concentrate, BD Pharmingen, San Jose, CA, USA), 1:1000
FITC Annexin V (BD Pharmingen), 0.333 µg/ml PI and
1.33 µg/ml Hoechst 33342 (Thermo Fisher Scientific)
were added to each well, and the plate was incubated for
20min at room temperature. High content screening was
performed using the ArrayScan™ XTI HCA Reader and
the HCS Studio Cell Analysis Software V6.6.0 (Thermo-
Fisher Scientific, Surrey, UK). The CrEST™ X-Light™
Confocal Scan Head (ThermoFisher Scientific) was inte-
grated into the ArrayScan™ Reader, which enabled the
capture of fluorescent microscopy images of cells. The
ArrayScan™ collected multiple images until a maximum
of 2000 cells was imaged per well.
Images were analysed using the HCS Studio Cell Ana-
lysis Software V6.6.0 (Thermo Fisher Scientific). Briefly,
the software calculated total death by quantifying cells
that were AV stained, PI stained or both (cells were
identified by nuclear Hoechst staining). This data was
then graphed using GraphPad Prism 8.0.
Caspase-3/7 activity assays
Caspase-3/7-Glo® reagent (25 μl) (Promega, South-
ampton, UK) was incubated with 5 μg of protein lysate
diluted in phosphate buffered saline in a total volume of
50 μl for 45 minutes at room temperature. Luciferase
activity was measured using a luminescent plate reader
(Biotek Synergy 4 plate reader).
Crystal violet assays
Cell viability was determined using crystal violet assays,
as previously published22.
Immunofluorescence
Cells were seeded into 8-well chambers (ThermoFisher
Scientific), incubated overnight and treated as required
(each treatment was performed across duplicate chambers
within an experiment). Cells were washed in phosphate
buffered saline and fixed in 4% paraformaldehyde. Cells
were incubated with Alexa-488 labelled Wheat Germ
Agglutinin (WGA) (Thermo Scientific Fisher, Cramling-
ton, 1:2000) at room temperature (RT) for 5 minutes.
Slides were then washed, permeabilised for 30minutes
(Tris-buffered saline, 10% goat serum (Abcam) and 0.1%
Saponin (Sigma)) and left to block overnight (Tris-buf-
fered saline, 5% Goat serum and 0.01% Saponin). Cells
were incubated with DR5 (1:100) antibody for 1 hour at
RT, followed by washing and were then incubated with
Alexa Fluor-568 anti-rabbit secondary antibody (Ther-
moFisher Scientific, 1:500) for 30 minutes at RT, followed
by washing. LAMP-1 (Abcam, 1:50) antibody was used in
conjunction with Alexa Fluor-488 anti-mouse secondary
antibody (ThermoFisher Scientific, 1:500). Counter-
staining and mounting were performed using VECTA-
SHIELD® anti-fade mounting medium with DAPI
(Vector Laboratories). Images were captured using a Leica
SP8 confocal microscope and a 63x lens at a 2x zoom,
1024 × 1024 frame and a 400 Hz scanning speed. Within
an experiment, images were taken using fixed laser set-
tings and exposure times. Images were acquired and
processed using Leica Application Suite X (Las X). DR5
colocalisation with TGN46, Calnexin and LAMP1 across
separate experiments was investigated using Manders’
colocalisation coefficient (MCC), which is a measure of
the co-occurrence of staining intensities in pixels above
threshold and was calculated using the JACOP plugin in
ImageJ. This enabled the fraction of total DR5 fluores-
cence colocalising with the fluorescence of the second
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marker (for e.g. TGN46) to be calculated. A threshold was
applied manually to all images using the built-in tool in
JACOP. A 90° rotation negative control, where the MCC
was re-calculated when the image of the second marker
was rotated 90° clockwise, was employed to confirm that
co-occurrence of staining was not random23.
Real-time reverse transcription-PCR analysis
RT-PCR analysis was performed using the LightCycler®
480 probes master mix (LightCycler® 480II, Roche).
ACTB and GAPDH were used as housekeeping genes.
RNA was isolated using the GeneJET RNA purification kit
(ThermoFisher Scientific); quantification and quality
control (ratios for 260/280 nm >1.8 and for 260/230 nm
>2) were performed using the NanoDrop™ One/OneC
Microvolume UV-Vis Spectrophotometer (ThermoFisher
Scientific). cDNA synthesis was performed using the
Moloney murine leukaemia virus-based reverse tran-
scriptase kit (Invitrogen, ThermoFisher Scientific). Cata-
logue numbers for real-time ready probes (Roche) are as
follows: RALA- 115411, RALB- 148403, TNFRSF10B-
101236, ACTB- 101125, GAPDH- 101128 and RALGDS-
145711. PCR primers for FLIPL and FLIPS were purchased
from Eurofins Genomics and were used in conjunction
with LightCycler® 480 SYBR Green I Master mix (Roche).
(FLIPL: Forward: 5′-CCT AGG AAT CTG CCT GAT
AAT CGA, Reverse: 5′-TGG GAT ATA CCA TGC ATA
CTG AGA TG; FLIPS: Forward: 5′-GCA GCA ATC CAA
AAG AGT CTC A, Reverse: 5′-ATT TCC AAG AAT
TTT CAG ATC AGG A).
siRNA transfections
siRNA transfections were carried out using HiPerfect
(Qiagen) as previously described15.
Analysis of clinical data
The stage II/III CRC patient cohorts GSE103479 (n=
156)24, the GSE39582 (n= 481)25 and GSE14333 (n=
185)26 datasets, and their consensus molecular subtypes
(CMS) and Colorectal Cancer Intrinsic Subtypes (CRIS)
classification have been described24. GSE59857 is a data-
set comprising transcriptomic data for 155 established
CRC cell lines. The COREAD dataset comprises protein
abundance data for 50 CRC cell lines27. For survival
analyses, the median value for RALB expression values
was identified using the probe set corresponding to RALB
(ADXECAD.28315_at and 202100_at). Patient samples
were then allocated to one of two categories: RALB low
and RALB high. Survival curves, comparing RALB low
(grey) with RALB high (black) expression groups, were
estimated with the Kaplan Meier method and compared
by the log-rank test, using GraphPad Prism version 8 for
Windows, GraphPad Software, La Jolla, CA, USA, www.
graphpad.com. To assess RALB protein expression in
clinical samples, we accessed fresh frozen matched CRC
primary and normal tissues, collected during 2001–2002
at the Belfast City Hospital (REC49/01). This work was
approved by the School of Medicine, Dentistry and Bio-
medical Science ethics committee (19.12V1). Consent was
obtained from all patients.
Statistical analysis
Statistical significance was calculated from distinct
technical replicates, by Student’s t-test (two-tailed, two-
sample equal variance on unpaired data), one-way or two-
way ANOVA in GraphPad Prism 8, unless specified
otherwise. One-way ANOVA tests were used where
multiple groups were compared to each other, whereas
two-way ANOVA tests were performed to compare two
factors (for e.g. siRNA and drug) across multiple groups.
Multiple comparison analyses (for 1- and 2-way ANOVA
tests) were performed using GraphPad Prism 8. Graphs
were plotted as means with error bars representing
standard deviation from the mean. Statistical significance
is denoted as follows: ****= p < 0.0001, ***= p < 0.001,
**= p < 0.01, *= p < 0.05, ns= p > 0.05. Experimental
phenotypes were confirmed in at least three independent
experiments, unless specified otherwise.
Results
RALB is required for the survival of KRASMT CRC cells
Previous data from our lab have shown that RALA, but
not RALB, regulates migration of KRASMT CRC cells28.
We determined whether these two structurally related
GTPases29 have similar roles in regulating the survival
of KRASMT CRC cells (Fig. 1A). Although silencing of
RALA resulted in minor decreases in the viability of
KRASMT and WT CRC cells, siRALB was found to affect
the viability of these cells to a greater extent. This was
confirmed using additional siRNA sequences against
RALB (Fig. S1A). Furthermore, overexpression of WT-
RALB or constitutively active G23V-RALB markedly
increased the colony-forming ability of KRASMT CRC
cells (Fig. 1A). Importantly, siRALB resulted in cell death
only in KRASMT but not in WT cells as determined by
PARP cleavage, sub-G1 levels and Caspase-3/7 activation
(Fig. 1B, C and Fig. S1A–C). siRALA did not induce cell
death in KRASMT CRC cells (Fig. 1B, C and Fig. S1D).
KRASMT cancers are unresponsive to MEK inhibition
(MEKi)30,31. A previous study has shown a role for RALB
in mediating resistance to knockdown of NRASV12 in
AML32. We therefore hypothesised that RALB has a
potential role in regulating resistance to MEKi in
KRASMT CRC. Co-treatment of RALB siRNA with the
MEKi AZD6244 resulted in significant increases in cell
death, determined by PARP cleavage, increased sub-G1
levels and Caspase-3/7 activity in HCT116 cells (Fig. 1B
and Fig. S1B). This was not observed in KRASWT CRC
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Fig. 1 (See legend on next page.)
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cells (Fig. 1B and Fig. S1C). We extended these studies to
include a panel of KRASMT (SW620, GP5D and LoVo)
cells. In contrast to the HCT116 cells, addition of
AZD6244 to siRALB resulted in no significant increases in
cell death compared to the effect of siRALB alone in these
cells (Fig. 1C and Fig. S1D). Furthermore, co-treatment of
AZD6244 with siRALA did not increase cell death in
KRASMT or WT cells. No consistent changes in expres-
sion levels of pERK1/2 were observed following siRALB or
siRALA. Collectively, these results indicate that RALB,
but not RALA, regulates survival of KRASMT but not
KRASWT CRC cells.
Clinical relevance of RALB in CRC
Analysis of RALB expression revealed higher RALB
levels in tumour compared to the matched normal patient
tissues (Fig. 1D). To improve CRC patient management in
the context of precision medicine, a recent study has
identified five CRIS subtypes, with KRAS frequently
mutated in CRIS-A, CRIS-B and CRIS-E13. Interestingly,
in three publicly available CRC transcriptomic patient
datasets (GSE39582/GSE103479/GSE14333)24–26, we
found significantly higher levels of RALB gene expression
in the poor prognostic CRIS-B subtype, compared to the
levels observed in any of the other CRIS subgroups (Fig.
1E and Fig. S2A). Similar findings were made in the
publicly available 155 CRC cell lines transcriptomic
dataset GSE59857 (Fig. S2B) and the 50 CRC cell lines
protein abundance COREAD dataset (Fig. 1D, lower)27.
To assess the prognostic value of RALB, we interrogated
an early-stage II/III CRC dataset (GSE103479). Analysis of
RALB mRNA expression (LOW versus HIGH-RALB) in
this dataset showed that, although patients with high
RALB expression had a decreased overall survival com-
pared to patients with low RALB expression (HR= 1.554;
95%-CI: 0.7701–3.135), this did not reach statistical sig-
nificance (p= 0.21) (Fig. S2C). Similar data were obtained
using a second early-stage dataset (HR= 1.339; 95%-CI:
0.7889–2.489; p= 0.25) (Fig. S2C). Collectively, these data
indicate that RALB is highly expressed in CRIS-B CRC, a
poor prognostic subgroup in need of novel treatment
strategies.
RALB depletion induces apoptosis in a Caspase-8-
dependent manner
A previous study in KRASMT NSCLC found that RALB
inhibits anchorage-independent growth in a p53-
dependent manner33. In contrast to this study, no
marked differences in cell death were found following
siRALB in our p53-WT parental and isogenic p53 null
HCT116 cells (Fig. S3A). Caspase-dependent apoptosis
following siRALB was assessed using the pan-caspase
inhibitor z-VAD-FMK, which completely attenuated
increased sub-G1 levels, activation of PARP and Caspases-
3/7 in KRASMT cells (Fig. 2A and Fig. S3B). To investi-
gate further the relative importance of the extrinsic and
intrinsic apoptotic pathways in mediating siRALB-
induced apoptosis, CRC cells were co-transfected with
siRALB and siCaspase-8 or siCaspase-9. Notably, co-
silencing of Caspase-8 with RALB resulted in inhibition of
siRALB-induced PARP and Caspase-3/7 activity in both
KRASMT HCT116 and SW620 cells (Fig. 2B). These
results were confirmed using the Caspase-8 null HCT116
cells (Fig. 2C). We previously reported that HCT116 cells
behave in a type II manner, with the extrinsic apoptotic
pathway requiring mitochondrial amplification via the
intrinsic apoptotic pathway in order to commit to apop-
tosis34. This model can explain why siCaspase-9 also
decreased siRALB-induced apoptosis in the HCT116 cells
(Fig. 2B). Collectively, these data suggest that the apop-
tosis induced by siRALB proceeds via a Caspase-8-
mediated activation of the extrinsic apoptotic pathway.
RALB depletion increases total and cell-surface DR5 levels
Given the Caspase-8-dependent manner of siRALB-
induced apoptosis, the expression of FLIPL/S, an
(see figure on previous page)
Fig. 1 RASMT CRC cells are dependent on RALB for survival. A Left: Crystal violet cell viability assay in KRASMT and KRASWT cells following
transfection with 10 nM scrambled control (SC), RALA (siRALA) or RALB (siRALB) siRNA for 72 h. Cell viability values are presented relative to SC and
the dashed line represents a 25% decrease in viability. Right: Clonogenic survival assay in HCT116 cells following transfection with 1 μg empty vector
(EV), RALB wild-type (WT) or RALBG23V constructs and incubation for 14 days. Western blot (WB) analysis of FLAG-tag carried out in HCT116 cells
transfected with EV, RALB-WT and RALBG23V constructs. β-actin was used as a loading control. B Top: WB analysis of PARP, RALA, RALB, pERK1/2T202/Y204
and ERK1/2 expression in HCT116 and LIM1215 cells, following transfection with SC, siRALA or siRALB and co-treatment with 1 μM AZD6244 for the
indicated time. Bottom: Apoptosis was assessed by propidium iodide (PI) flow cytometry and Caspase-3/7 activity levels in HCT116 and LIM1215 cells,
following transfection with SC, siRALA or siRALB and co-treatment with 1 μM AZD6244 for 24 h. C SW620 and GP5d cells were transfected with SC,
siRALA or siRALB and co-treated with 1 μM AZD6244. PARP, RALA, RALB, pERK1/2T202/Y204 and ERK1/2 expression was determined by WB and β-actin
was used to assess equal loading. Apoptosis was assessed by PI flow cytometry and by measuring Caspase-3/7 activity. D Top: WB analysis showing
RALB expression in matched CRC (T) and normal (N) tissues. Equal loading was assessed by analysing β-actin expression. Bottom: Boxplots
representing RALB protein abundance across CRIS subgroups in the COREAD dataset. E Boxplots representing the log2 gene expression values for
RALB (probes ADXECAD.28315_at and 202101_s_at) across CRIS subgroups in GSE103479 and GSE14333 clinical datasets. Numbers underneath the
boxplots (n) indicate the sample number per group.
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Fig. 2 RALB silencing induces Caspase-8-dependent apoptosis. A HCT116 cells were transfected with 10 nM SC, siRALA or siRALB and pre-
incubated with DMSO or 20 μM of the pan-caspase inhibitor, z-VAD-FMK for 3 h followed by treatment with 1 μM AZD6244 for 24 h, following which
apoptosis was assessed by PI flow cytometry (left), WB analyses for PARP and cleaved Caspase-8 (middle) and Caspase-3/7 activity assays (right). B CRC
cells were transfected with 10 nM C8 or C9 siRNA for 24 h and were thereafter transfected with 10 nM RALB siRNA for 24 h. Apoptosis was assessed by
WB analysis for cleaved Caspase-8, Caspase-9 and Caspase-3 (left) and Caspase-3/7 activity (right). C Paired CRISPR HCT116Caspase-8+/+ and
HCT116Caspase-8-/- cells were transfected with 10 nM SC, RALA or RALB and co-treated with 1 µM AZD6244 for 24 h. Apoptosis was determined by WB
for PARP, Caspase-8 (* indicates a non-specific band) and Caspase-7 (left), Caspase-3/7 activity levels (right, top) and PI flow cytometry (right, bottom).
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endogenous inhibitor of Caspase-8 activation, was asses-
sed (Fig. S3C). Although FLIPL mRNA levels were found
to be slightly increased in the siRALB-transfected cells,
FLIPL protein levels were unaffected. To further investi-
gate the upstream mechanisms specifically involved in
siRALB-induced apoptosis, a protein array was used to
assess simultaneously the expression of 35 human
apoptosis-related proteins in KRASMT cells, following
transfection with siRALB, siRALA or siRALGDS (Fig. 3A
and Fig. S4A–F). Notably, siRALB induced both pro-
apoptotic and anti-apoptotic signalling responses. Sig-
nificantly (2-fold cut-off; p < 0.05) increased levels of DR5/
TRAIL-R2, XIAP and the anti-apoptotic Bcl2-family
member Bcl-xL were found following siRALB; these did
not change in the siRALA-transfected cells. We validated
these array results by western blotting (Fig. 3A). Impor-
tantly, only DR5 levels increased dramatically as early as
24 h following transfection with siRALB but not in the
siRALA or siRALGDS-transfected cells. DR4 was upre-
gulated in both RALA and RALB knockdown cells. DR5
upegulation was confirmed with three additional siRNA
sequences (Fig. S5A) and in three additional KRASMT
CRC cell lines (Fig. 4A). The DR5 upregulation observed
in RALB-silenced cells was not an indirect result of cas-
pase activation, as inhibition of apoptosis using the
Caspase-8 null HCT116 cells failed to prevent DR5
upregulation in RALB-silenced cells (Fig. S5B). Interest-
ingly, silencing of RALB did not increase DR5 levels in
KRASWT cells (Fig. S5C). Using immunofluorescence
confocal microscopy, we further showed that siRALB
resulted in a significant increase in DR5 staining intensity
(Fig. 3A and Fig. S5D). Furthermore, DR5 cell-surface
expression analysis in siRALB-transfected cells confirmed
these results (Fig. 3B and Fig. S5E). Previous studies have
shown that DR5 can signal from the intracellular ER-
Golgi compartment, independently of TRAIL35. We
therefore assessed the impact of RALB depletion on
colocalisation of the Golgi marker TGN46 and the
Endoplasmic Reticulum marker Calnexin with DR5, and
found no increases in colocalisation of the two markers
with DR5 when RALB was silenced (Fig. S5F, G).
Although no significant negative correlations were
observed between RALB and DR5 protein levels within
the CRIS-B group, we found that the DR5/RALB ratio was
the lowest in the CRIS-B group compared to the other
CRIS subgroups (Fig. S2D–F).
siRALB-induced apoptosis is DR5-dependent
To investigate whether DR4/TRAIL-R1 contributes in a
similar manner to DR5 in regulating siRALB-induced
apoptosis, specific siRNAs were used to decrease the
expression of each receptor (Fig. 3C). Depletion of
DR4 slightly reduced the Caspase-3 cleavage and Caspase-
3/7 activity observed following siRALB in HCT116 cells
(Fig. 3C). In contrast, co-silencing of DR4 and RALB in
the SW620 cells did not decrease apoptosis compared to
the levels observed with siRALB alone. Importantly, siDR5
completely abrogated siRALB-induced PARP, Caspase-3
cleavage and Caspase-3/7 activity in both KRASMT cell
lines (Fig. 3C). These data were validated using WT and
DR5-knockout HCT116 cell lines (Fig. 3D and Fig. S4G).
Canonically, DR5-mediated activation of Caspase-8 and
apoptosis is triggered following ligation of its ligand
TRAIL, which is normally expressed on the cell surface of
various immune cells36. Notably, co-incubation with a
TRAIL neutralising antibody failed to rescue siRALB-
induced apoptosis in KRASMT CRC cells (Fig. 3E). Taken
together, these results would suggest a causal role for
DR5, but not for DR4, in the cell death following siRALB
in KRASMT CRC.
RALB reduces DR5 expression through enhancing
lysosomal degradation
Previous studies have shown that DR5 may be tran-
scriptionally upregulated by p5337 and that depletion of
RAL-GTPases can stabilise p5333. We therefore analysed
if the increased DR5 levels observed following siRALB was
a result of transcriptional changes. Quantitative-PCR
analysis showed that silencing of RALB, and not RALA,
resulted in minimal increases in TNFRSF10B mRNA
levels (1.19–1.46 fold) (Fig. 4A and Fig. S5H). No changes
in expression levels of CHOP or the NFκB-inhibitor alpha
(IKBα) protein, key transcriptional activators of DR538,39,
were observed following siRALB (Fig. S5I). In addition,
sip65 did not affect basal DR5 levels (Fig. S5I). Silencing of
RALB resulted in minimal increased (1.26–1.36-fold)
TP53 mRNA and protein levels (Fig. 4A). Although
siRALB-induced DR5 upregulation was partially abro-
gated in the TP53 null HCT116 model (Fig. 4A), we also
found strong DR5 increases following siRALB in SW620
cells expressing the clinically relevant DNA-binding-
defective mutant p53-R273H (Fig. 4A and Fig. S5E).
These results indicate that siRALB-induced DR5 upre-
gulation can occur independently of p53.
Beyond a regulator of transcription factors, RALB is
involved in vesicular trafficking and activation of the
autophagosome/lysosome assembly, and this function
may contribute to the accumulation of DR5 in RALB
knockdown cells (Fig. 3A)40. Furthermore, a number of
previous studies have shown autophago-lysosomal reg-
ulation of DR5 levels41. Therefore, we next determined
the impact of RALB depletion on DR5 lysosomal degra-
dation, using the lysosomal inhibitor chloroquine (CQ)
(Fig. 4B). In agreement with other studies, we found that
CQ resulted in increased DR5 levels42. Furthermore,
siRALB markedly enhanced the upregulation of DR5
induced by CQ, while there was no further change in the
autophagy marker LC3. Similar data were obtained using
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the lysosomal inhibitor Bafilomycin A1 (Fig. 4B)43. In
addition, transient overexpression of RALB abrogated the
increased DR5 expression levels following CQ treatment
(Fig. 4B). Importantly, overexpression of RALB resulted in
increased colocalisation of endogenous DR5 with LAMP1,
as indicated by the MCC values, demonstrating that
RALB regulates lysosomal localisation of DR5 (Fig. 4C
and Fig. S5J). The proteasomal inhibitor MG132 did not
affect siRALB-induced DR5 levels (Fig. S5K, left panel).
We also compared the effect of siRALB on DR5 stability
using the protein synthesis inhibitor cycloheximide. The
result showed that the degradation rate of DR5 was
unchanged in siRALB-transfected cells (Fig. S5K, right
panel). Collectively, these data indicate that RALB can
regulate DR5 protein levels by altering its trafficking to
the lysosomal compartment for degradation (Fig. 4D).
RALB depletion sensitises KRASMT CRC cells to rhTRAIL
A number of studies have indicated that cell-surface
TRAIL-receptor expression levels correlate with TRAIL-
resistance/sensitivity44,45. As our results described above
show that RALB depletion increases total and cell-surface
DR5 levels, we hypothesised that RALB may be addi-
tionally involved in regulating sensitivity to TRAIL
treatment in KRASMT CRC. Notably, rhTRAIL treatment
markedly increased PARP, Caspase-8, -9 and -3 cleavage
in RALB-silenced KRASMT cells (Fig. 5A). These results
were confirmed quantitatively using Caspase-3/7 activity
assays and Annexin V/propidium iodide staining (Fig. 5A,
B). In addition, cell viability of RALB-depleted, rhTRAIL-
treated KRASMT cells was significantly decreased com-
pared with control siRNA-transfected cells (Fig. 5C).
Similar effects were observed in a panel of KRASMT CRC
cells and using two additional RALB siRNA sequences
(Fig. S6A, B). Notably, RALB expression was acutely
increased in 6/7 KRASMT cell lines in response to
rhTRAIL treatment (Fig. 5A and Fig. S6A).
The results described above clearly indicate that RALB
downregulation sensitises KRASMT CRC cells to
rhTRAIL-induced apoptosis. Previous studies have shown
that Dinaciclib, a broad spectrum cyclin-dependent kinase
inhibitor, is an efficient suppressor of CDK5-mediated
activation of RALB32. In HCT116 cells treated with
Dinaciclib, RALB activity was downregulated (Fig. 5D). In
agreement with the results in RALB-depleted cells,
Dinaciclib potently increased rhTRAIL-induced apoptosis
(Fig. 5D). Similar results were obtained in the KRASMT
SW620 and GP5d cells (Fig. S6C). Collectively, these
findings indicate that RALB-targeted agents may be highly
effective when used in conjunction with DR5 agonists to
treat KRASMT CRC.
RALB associates with the DR5-DISC in a Caspase-8-
dependent manner
To further elucidate the mechanism by which RALB
regulates rhTRAIL sensitivity, we examined the effect of
DR5 agonists on RALB subcellular localisation. Fractio-
nation experiments showed that the primary localisation
for both RALB and DR5 is the membrane in untreated
CRC cells (Fig. 6A). To investigate whether RALB
associates with the plasma membrane-bound DR5
receptor, we used the agonistic antibody AMG 655 that
binds the extracellular domain of DR5. Our experiments
showed that RALB was recruited to the DISC as soon as
3 h following incubation with AMG 655 (Fig. 6B, top left
and Fig. S6D). As published previously20, FLIPL was pre-
sent at the DISC exclusively in its Caspase 8-processed
p43-form and FLIPS, FADD and Caspase-8 were also
recruited. The clathrin adaptor protein 2 (AP-2) inter-
acted with DR5 at the earliest time point indicating that
(see figure on previous page)
Fig. 3 RALB silencing regulates DR5 expression levels. A Top Left: HCT116 cells were transfected with 10 nM SC, siRALA, siRALB or siRALGDS for
24 h, following which cells were harvested for protein extraction. Protein was subsequently analysed using a human apoptosis array. Densitometry
was performed on the array panels using ImageJ software, and results for DR4, DR5, Fas/CD95, FADD and TNFR1/TNFRSF1A are shown. Top right:
PARP, DR5, DR4, FADD, XIAP, Bcl-xL, RALA and RALB levels in CRC cells following RALA, RALB and RALGDS silencing for the indicated times. Bottom
left: Wheat germ agglutinin (WGA), a lectin that binds N-acetylglucosamine post-translational modifications on membrane receptors, was used as a
plasma membrane marker. Fixed cells were stained with Alexa488-WGA prior to permeabilisation to minimise the staining of glycosylated proteins in
the Golgi apparatus. A single confocal image was collected of the Alexa488-WGA stained membrane (green) alongside immunostained endogenous
DR5 (red). Laser settings were kept constant between the samples to enable the comparison of membrane-associated DR5 staining in control (SC)
and siRALB-treated cells. Bottom right: >20 cells were scored for intensity in ImageJ. The intensity was normalised to cellular area and plotted. The
data are representative of three independent experiments. B CRC cells were transfected with 10 nM SC or siRALB for 24 h and DR5 cell-membrane
expression was assessed by flow cytometry using a DR5-specific phycoerythrin-conjugated mAb. Expression was compared with an isotype-matched
control antibody (IgG control). Geometric means (GM) for fluorescence intensity were plotted and significance was analysed using an unpaired t-test.
C CRC cells were transfected with 10 nM siRNA targeting DR4 or DR5 for 24 h and were thereafter transfected with 10 nM RALB siRNA for 24 h.
Apoptosis was assessed using WB for PARP, cleaved Caspase-8 and Caspase-3 (top) and Caspase-3/7 activity (bottom). (Asterisk next to the western
blot indicates an unspecific band). D Paired CRISPR parental (control= CT) and DR5 knockout (KO) cells were transfected with 10 nM SC or RALB
siRNA (siRB) for the indicated time. Apoptosis was determined by WB for PARP, Caspase-8 and Caspase-3 (left), Caspase-3/7 activity (right, top) and PI
flow cytometry (right, bottom). E WB analysis for PARP and Caspase-8 (left) and Caspase-3/7 activity (right) of the effect of TRAIL neutralising antibody
(nAb) treatment (100 ng/ml) on cell death in HCT116 cells transfected for 48 h with 10 nM SC or siRALB.
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endocytosis of the receptor–ligand complex is initiated at
the plasma membrane upon ligand binding. Interestingly,
increased proteolytic cleavage of the α subunit of AP2
(AP2α) occurred in a time-dependent manner, consistent
with the results of a previous study46. The unbound
fraction showed decreases in pro-Caspase 8 and FADD
over time, consistent with increased recruitment of DISC
components to the membrane in response to AMG 655
treatment (Fig. 6B, top right). Notably, silencing of RALB
markedly reduced RALB recruited to the DISC, 1 h and
3 h following incubation with AMG 655 (Fig. 6B, bottom).
We further investigated TRAIL-induced RALB recruit-
ment to the DR5-DISC by immunoprecipitating FLAG-
tagged RALB from untreated and TRAIL-treated cells and
then immunoblotting for the presence of Myc-tagged
DR5 (Fig. 6C). In agreement with the results described
above, binding of RALB to DR5 occurred in TRAIL-
treated cells. Furthermore, TRAIL treatment failed to
recruit RALB to the DR5-DISC in Caspase-8 null cells,
suggesting that the interaction between DR5 and RALB is
Caspase-8-dependent (Fig. 6D).
To investigate further if RALB plasma membrane
localisation and/or its GDP/GTP-bound state was
required for its recruitment to the DR5-DISC in response
to AMG 655 treatment, we used FLAG-tagged WT,
constitutively-active (G23V), dominant-negative (S28N)
and geranylgeranylation-deficient (C203S) MT RALB
expression constructs (Fig. 6E). RALB C203S does not
undergo geranylgeranylation at its C-terminal domain and
is localised in the cytosol fraction47. Binding of RALB to
the DR5-DISC was attenuated by the C203S-MT but not
the S28N-MT, when compared to WT-RALB in AMG
655-treated cells (Fig. 6E). Interestingly, a decreased
association of G23V-RALB with the DR5-DISC was
observed compared to WT or S28N-RALB, suggesting
that constitutively active RALB has a higher turnover rate
and may be removed from the plasma membrane more
rapidly, compared to WT-RALB. Notably, transient
overexpression of WT-RALB attenuated TRAIL-induced
apoptosis in HCT116 CRC cells (Fig. 6F). AMG 655-
induced apoptosis was unaffected and slightly increased
following transient overexpression of G23V-RALB, S28N-
RALB and C203S-RALB MT expression constructs,
respectively (Fig. 6E, lower panel). Taken together, these
results are the first to our knowledge to demonstrate the
importance of RALB in regulating sensitivity to TRAIL
treatment in KRASMT CRC.
Discussion
Identification of novel therapeutic strategies that can
induce effective KRASMT-tumour-cell killing remains an
unmet need1. So far, all attempts to interfere with onco-
genic RAS signalling have failed in the clinic. In particular,
combinations of inhibitors of the MAPK and PI3K/Akt
RAS effector signalling have been shown to be ineffective
in KRASMT CRC4, suggesting the involvement of addi-
tional effector pathways in mediating KRAS oncogenic
signalling. In this study, we provide evidence that the
RALB-GTPase is an important regulator of RASMT
cancer cell survival and that inhibition of RALB ‘primes’
KRASMT cells to death upon stimulation with DR5-
agonistic antibodies.
(see figure on previous page)
Fig. 4 DR5 expression is regulated by RALB through lysosomal degradation and p53-mediated transcription. A Left: HCT116 cells were
transfected with 10 nM of SC or 4 different siRNA sequences targeting RALB for 24 h. TNFRSF10B (upper) and RALB (lower) mRNA was quantified using
RT-PCR. Raw values were normalised to the expression of housekeeping genes ACTB and GAPDH and were analysed using the ΔΔCT method. mRNA
levels presented are relative to SC. Middle top: HCT116 p53 wild-type (WT) and null cells were transfected with either 10 nM SC or siRALB (two
different sequences) for 24 h and the protein expression of p53, DR5 and RALB was determined using WB. Middle bottom: HCT116 cells were
transfected with 10 nM of SC or four different siRNA sequences against RALB for 24 h. TP53 mRNA was quantified using RT-PCR. Analysis was
performed as described above. Right: SW620, GP5d and LoVo cells were transfected with 10 nM SC or RALB siRNA (_6) for 24 h and DR5 expression
was determined by WB. B Left: HCT116 cells were treated with siRNA targeting either SC or RALB for a total transfection time of 24 h. Cells were
treated with 20 µM Chloroquine (CQ) for 4, 6 or 8 h. The expression of DR5, RALB, LC3-A/B and β-actin was analysed using WB. The numbers at the
bottom of the WB panel represent densitometry performed on the DR5 blot using ImageJ. Middle: HCT116 cells were transfected with siRNA
targeting either SC or siRALB and were treated with 50 nM Bafilomycin A1 for 3 h for a total transfection time of 24 h. The expression of DR5, RALB
and β-actin was analysed using WB. The numbers at the bottom of the WB panel represent densitometry performed on the DR5 blot using ImageJ.
Right: HCT116 cells were transfected with 1 µg of a WT FLAG-tagged RALB construct for 24 h followed by treatment with 20 µM Chloroquine for a
further 24 h and DR5 and FLAG-tag expression was determined by WB. C Top: HCT116 cells were transfected with either empty vector (EV) or FLAG-
RALB WT for 24 h. Cells were then fixed, permeabilised, blocked and stained with a lysosomal marker LAMP1, and DR5 antibody. Bottom left:
Manders’ colocalisation coefficient (MCC) was calculated using ImageJ to measure the fraction of total DR5 fluorescence overlapping with LAMP1
fluorescence for each treatment and is presented in the ‘Merge’ image rounded to two decimal places. Image presented is representative of three
independent experiments. Additional cells are presented in Fig. S5J. The MCC was calculated for over 50 cells across each treatment group over three
independent experimental repeats and the analyses are presented in the graph. A 90° rotation negative control was employed to ensure
colocalisation was not random. A Kruskal Wallis one-way ANOVA with a multiple comparisons test was performed in Prism to statistically analyse the
data. Error bars represent standard deviation from the mean. Bottom right: HCT116 cells were transfected with either EV or FLAG-RALB WT for 24 h,
and FLAG and DR5 expression was determined by WB. D Schematic of the role of RALB in regulating DR5 expression levels.
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Previous studies have shown that RAL-GEF pathway
activation is one of the basic requirements for RAS-
mediated transformation of human epithelial cells7,8 and
that RALA and RALB have both distinct and/or over-
lapping roles in regulating migration/invasion and
anchorage-independent growth in pancreatic, bladder and
prostate cancer11,48. In agreement with a previous study in
a range of cancer cell models49, we found that RALB, and
not RALA, has a profound effect on the survival and
apoptosis of CRC cells, in particular in KRASMT CRC.
Contrary to a previous study from Martin et al.50, our
study showed that overexpression of RALB markedly
increased the colony-forming ability of KRASMT CRC
cells. Our previous studies and those of others have
shown that MEK1/2 inhibition is relatively ineffective at
inducing apoptosis in KRASMT CRC cells15. An impor-
tant finding of our study is that neither the RALB nor the
RALA RAS effector pathways are involved in regulating
resistance to MEK1/2 inhibition in KRASMT CRC. Taken
together, we demonstrate here for the first time a key role
for RALB as a regulator of survival in KRASMT CRC.
High RALB expression has been reported in several
tumours, including lung cancer, and has been identified as
a poor prognostic marker in these tumours51. In this
study, we found that RALB was overexpressed in CRC
tissues compared to matched normal colon tissue, high-
lighting the potential for exploitation of RALB as a ther-
apeutic target in CRC. Stage II/III CRC patients with high
RALB expression trended towards poorer overall survival
but the data were not statistically significant. Importantly,
further analysis revealed that the highest levels of RALB
are detected in CRIS-B CRC, the subgroup that is char-
acterised by invasive, epithelial-to-mesenchymal transi-
tion features and strong TGF-β activity, which is
associated with a worse outcome13. Previous studies have
also shown a positive correlation between RALB and an
invasive, aggressive and metastatic phenotype in bladder
and pancreatic cancer10,52. These results would indicate
that anti-RALB selective therapies may provide an effec-
tive therapeutic approach for KRASMT CRIS-B CRC with
high expression levels of RALB.
Several studies have shown that downregulation of
RALB results in apoptosis and increased drug sensitivity
through de-phosphorylation of TBK1, resulting in
decreased expression of NF-κB target pro-survival genes
(e.g. Bcl-2)53,54. In contrast to these studies, our data did
not show a role for TBK1 in mediating siRALB-induced
apoptosis (Fig. S6E). However, the mechanism by which
RALB silencing induces apoptosis was shown to involve
Caspase-8-dependent apoptosis following upregulation of
cell surface and total DR5 levels. This is the first
demonstration of a link between RALB and DR5 expres-
sion. Moreover, using receptor-specific siRNA and a DR5
CRISPR knockout model, we further found that induction
of apoptosis following siRALB was mediated by DR5, but
not DR4.
It was previously shown that DR5 cell-surface levels are
a critical mediator to TRAIL-induced apoptosis46,55.
Consistent with this newly identified association between
RALB and DR5, we have shown that inhibition of RALB
through specific siRNA or the broad spectrum cyclin-
dependent kinase inhibitor Dinaciclib significantly sensi-
tised KRASMT CRC cells to TRAIL treatment. We also
found that transiently overexpressing RALB decreased
DR5 levels and apoptosis in response to TRAIL treatment.
Of note, this is also the first study showing that stimula-
tion of DR5 results in a rapid and Caspase-8-dependent
association of RALB with the DR5-DISC, which only
occurred when RALB was able to translocate to the
plasma membrane. Several clinical trials using fully
human DR5-agonistic antibodies, including AMG 655,
have been unable to show meaningful clinical efficacy56,
suggesting inherent resistance of primary tumours to DR5
activation-induced apoptosis. Our finding indicates a
novel and effective way to enhance DR5 activation-
induced apoptosis, in particular for KRASMT CRC.
Given its potential role in resistance to DR5-agonistic
agents, we further investigated how DR5 expression levels
are regulated by RALB. This is the first study showing that
RALB regulates DR5 protein levels through the lysosomal
degradation pathway. A number of reports have shown
that DR5 levels are controlled by the lysosomal, but not
(see figure on previous page)
Fig. 5 RALB inhibition enhances TRAIL-induced apoptosis in KRASMT CRC. A CRC cells were transfected with 10 nM RALB siRNA for 24 h prior to
treatment with rhTRAIL for the indicated time, (CT= control, untreated sample). Apoptosis was determined by using WB analysis for PARP, cleaved
Caspase-8, -9 and -3 levels (top) and Caspase-3/7 activity (bottom). LE= long exposure. B HCT116 and SW620 cells were transfected with either SC or
siRALB for 24 h followed by rhTRAIL treatment for a further 24 h. Apoptosis was assessed using Annexin V/propidium iodide (PI) staining by high-
content screening. The graph indicates the percentage of positive stained cells. C HCT116 and SW620 CRC cells were transfected with siRALB or
control siRNAs and then treated with the indicated doses of rhTRAIL for 72 h. An MTT assay was used to evaluate cell viability, which is presented
relative to SC control on the graphs. The dashed line indicates a 50% change in cell viability. D HCT116 cells were treated with Dinaciclib for 24 h,
prior to treatment with rhTRAIL for 24 h. WB analysis for PARP, cleaved Caspase-8 and -3 (Left top), Caspase-3/7 activity assays (left bottom) and PI
flow cytometry analysis of the sub-G1 apoptotic population (right bottom). HCT116 cells were treated with Dinaciclib for 48 h and expression of active
(GTP-bound) and total RALB was evaluated using WB. CT refers to an untreated sample (right top).
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the proteasomal degradation pathway42,57. Additional
studies have shown that DR5 co-localises and interacts
with LC3-II in autophagosomes, in particular in TRAIL-
resistant cells55. These reports show that lysosomal inhi-
bition increases cell-surface DR5 levels, as knockdown of
RALB did in our study (Fig. 3A, B). Using transient
overexpression of RALB, we found that DR5 co-localises
with lysosomes in KRASMT CRC cells. These results
would indicate that anti-RALB selective therapies may
suppress DR5 lysosomal degradation, increasing cell
membrane DR5 levels and thereby augmenting sensitivity
to DR5-agonistic antibodies.
In conclusion, we have shown that RALB inhibition
regulates DR5 dynamics and induces apoptotic priming,
and that targeting this apoptotic vulnerability with selec-
tive DR5-agonistic antibodies may be a promising strategy
to improve treatment response in KRASMT CRC
tumours. Furthermore, the study has uncovered a novel
RALB-DR5-DISC complex with RALB overexpression
suppressing TRAIL-induced apoptosis. Importantly,
RALB is highly expressed in the poor prognostic CRIS-B
CRC subgroup. From a clinical perspective, our data
provides the preclinical rationale for the initiation of a
phase I study of RALB inhibition with novel multivalent
TRAIL receptor 2/DR5 agonists (eg. MEDI3039)58,59 in
KRASMT CRIS-B CRC with high expression levels of
RALB. Our findings also support the development of new
and specific anti-RALB molecules that may provide tools
to investigate the biology and therapeutic potential of
RALB in CRC as they become available21.
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Fig. 6 rhTRAIL treatment results in association of RALB with the DR5-DISC (DR5-bound death-inducing signalling complex). A Membrane
(MF) and cytosolic (CF) fractions were isolated from HCT116 cells, and equal amounts of protein were immunoblotted for DR5, RALB, EGFR and MEK1/2.
WCL=whole-cell lysate B Top: WB analysis of DR5-DISC IP performed in HCT116 cells. The DR5-DISC was captured magnetically after the addition of
AMG 655-conjugated beads to cells for the indicated times. Co-immunoprecipitation of RALB, AP2α, FLIP, FADD and Caspase-8 was assessed and
pull-down of DR5 confirmed. Protein expression in the non-DISC recruited fraction (unbound fraction) was also analysed. Bottom: HCT116 cells were
transfected with either SC or siRALB for 24 h. A DR5-DISC IP was performed as described above, following a 1 h and 3 h incubation with AMG 655-
conjugated beads. Co-immunoprecipitation of RALB, FLIP, FADD and Caspase-8 was assessed and pull-down of DR5 confirmed. Protein expression in
the non-DISC recruited fraction (unbound fraction) was also analysed. C HCT116 cells were transiently transfected with empty vector (EV), FLAG-RALB
WT and C-terminal Myc-tagged long isoform of DR5 (DR5L) for 24 h followed by incubation with 0.5 ng/ml isoleucine zipper (iz)-TRAIL for 5 h. FLAG-
RALB was immunoprecipitated using Anti-FLAG® M2 dynabeads and the expression of Myc-tag and FLAG-tag was determined by WB. Protein
expression for Myc and FLAG were also determined by WB in the input lysates. D HCT116Caspase-8+/+ and HCT116Caspase-8−/− cells were incubated
with AMG 655-conjugated dynabeads for 1 h and 3 h. The DR5-DISC was isolated and expression of RALB, Caspase-8, FLIP, FADD and DR5 was
determined by WB. Protein expression in the unbound fraction was also analysed. E Top: HCT116 cells were transiently transfected for 24 h with 1 µg
of EV, FLAG-RALB WT, FLAG-RALB G23V (constitutively active), FLAG-RALB S28N (dominant negative) or FLAG-RALB C203S (geranyl-geranylation
deficient) for 24 h. The DR5-DISC was captured 3 h after the addition of AMG 655-conjugated beads to cells. Co-immunoprecipitation of FLAG-RALB
was assessed and pull-down of DR5 was confirmed using WB analysis. Protein expression for FLAG in the unbound fraction was also analysed.
Densitometry was performed on the DR5-DISC bound FLAG-RALB blot using ImageJ software and the results (intensity values) are denoted below
the blot. Nd= not detected. Bottom: Apoptosis in the unbound fraction was determined using a Caspase-3/7 activity assay. F HCT116 cells were
transiently transfected with EV or FLAG-RALB WT for 24 h, followed by treatment with rhTRAIL for 3 h. Expression of PARP, cleaved Caspase-3, FLAG-
tag and DR5 was determined by WB (top). Apoptosis was determined using a Caspase-3/7 activity assay (bottom).
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